X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Danicopan is an investigational oral medicine in development as an add-on to C5 inhibitor therapy eculizumab or ravulizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular haemolysis.
Lead Product(s): Danicopan,Ravulizumab,Eculizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: ALXN2040
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor and is approved in Japan for the treatment of adults with Neuromyelitis Optica Spectrum Disorder.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor and is approved in Japan for the treatment of adults with refractory generalised myasthenia gravis.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor and is approved in China for the treatment of adults with refractory generalised myasthenia gravis.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor and approved in China for the treatment of adults with refractory generalised myasthenia gravis.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor and approved in China for the treatment of adults with refractory generalised myasthenia gravis.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
ALXN2040 (danicopan) is an investigational oral medicine in development as an add-on to standard of care C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab) for patients with PNH who experience clinically significant EVH.
Lead Product(s): Danicopan,Eculizumab,Ravulizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: ALXN2040
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
Epysqli™ (eculizumab) is a mAb that specifically binds to the complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 mediated intravascular hemolysis in PNH patients.
Lead Product(s): Eculizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Epysqli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Soliris (eculizumab) is a first-in-class C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system.
Lead Product(s): Eculizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
The study met its primary endpoints, demonstrating no clinically meaningful differences between ABP 959 (eculizumab) and SOLIRIS based on control of intravascular hemolysis as measured by lactate dehydrogenase (LDH) at week 27 for the parallel comparison.
Lead Product(s): Eculizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: ABP 959
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Phase 3 study demonstrated clinical equivalence in efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SB12 compared to reference eculizumab in paroxysmal nocturnal hemoglobinuria patients.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: SB12
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines, which includes Soliris, in areas of immunology with high unmet medical needs.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $39,000.0 million Upfront Cash: $13,300.0 million
Deal Type: Acquisition July 21, 2021
Details:
AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs.
Lead Product(s): Eculizumab
Therapeutic Area: Immunology Product Name: Soliris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $39,000.0 million Upfront Cash: $13,300.0 million
Deal Type: Acquisition December 12, 2020
Details:
While there are no data supporting the role of terminal complement in coronaviral pneumoni, company sees the use of SOLIRIS® in patients with coronaviral infection with severe pneumonia or ARDS.
Lead Product(s): Eculizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
To date, SB12 (AMT904) is the only biosimilar candidate referencing Soliris® (eculizumab) to be granted IND approval in China.
Lead Product(s): Eculizumab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
